Background {#Sec1}
==========

*Mycoplasma pneumoniae* (*M. pneumoniae*) is one of the most common causes of community acquired pneumonia (CAP) often seen in children and young adults, and accounts for 10--39% of all cases of adult CAP cases \[[@CR1], [@CR2]\]. *M. pneumoniae* pneumonia is typically mild and characterized by a persistent dry cough or self-limiting pneumonia that resolves with no medication \[[@CR3]\]. However, respiratory failure and severe acute respiratory distress syndrome (ARDS) occur in 0.5--2% of all *M. pneumoniae* pneumonia cases and primarily affect young adults \[[@CR4]--[@CR18]\]. The rates of intensive care unit (ICU) admission of hospitalized *M. pneumoniae* pneumonia patients are reported as 10% in the US and 16.3% in Europe \[[@CR19], [@CR20]\]. The rate of ICU admission is even higher at 38.8% in patients older than 65 years, compared to 18% in patients older than 19 years \[[@CR20]\]. In one retrospective study from our hospital, 4.1% of *M. pneumoniae* pneumonia patients needed ICU admission for acute respiratory failure in the setting of an epidemic \[[@CR21]\].

Severe ARDS and fatal outcome as a result of *M. pneumoniae* pneumonia may be the result of unclear clinical features \[[@CR5]\], delayed diagnosis, inappropriate respiratory support, and/or insufficient initial treatment. When acute nonbacterial pneumonia progresses, *M. pneumoniae* must be considered as a possible cause, and appropriate diagnosis, respiratory support and therapeutic measures should be promptly instituted. Previous studies suggest that *M. pneumoniae* infection should be included in the differential diagnosis of ARDS, and that establishing an early diagnosis may have important therapeutic implications \[[@CR22]\].

In recent years, rapid diagnostic methods have been developed, allowing for early diagnosis of *M. pneumoniae* pneumonia. Detection of *M. pneumoniae* using fluorescence-quantatitive PCR in respiratory samples \[[@CR19], [@CR21]--[@CR24]\] and metagenomic next-generation sequencing (mNGS) has increased \[[@CR25]\]; these methods are especially useful for early detection of rare, atypical, and slow-growing microbes. Case reports have also described using new forms of respiratory support for *M. pneumoniae* pneumonia induced ARDS, such as high-flow nasal cannula (HFNC) \[[@CR26]\], non-invasive ventilation (NIV) \[[@CR27]\] and veno-venous extracorporeal membrane oxygenation (ECMO) \[[@CR18], [@CR24], [@CR28]\]. However, there has not yet been a full evaluation of the new available diagnostic and therapeutic measures in *M. pneumoniae* pneumonia induced ARDS.

The aim of our study was to describe a case series of 10 patients with *M. pneumoniae* pneumonia induced ARDS and provide an overview of available modalities for diagnosis and treatment. We describe the epidemiological, clinical, imaging, and laboratory features of our patients, review the available procedures for early diagnosis, and evaluate available respiratory support techniques in clinical practice in order to highlight the importance of rapid recognition and appropriate treatment.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

We retrospectively identified all cases of young and adult patients (age over 14 years) with ARDS caused by *M. pneumoniae* pneumonia who were admitted to the respiratory ICU in two teaching hospitals (Beijing Chao-Yang Hospital and Beijing Luhe Hospital, Beijing, China) with radiographically confirmed CAP from November 2017 to October 2019. The study was approved by the institutional review boards (IRB) at each institution. Written informed consent was obtained from all participants, where participants are children (under 16 years old) from their parent or guardian.

Case definitions for *M. pneumoniae* pneumonia induced ARDS {#Sec4}
-----------------------------------------------------------

Criteria for diagnosis of *M. pneumoniae* pneumonia were based on 1) clinical signs and symptoms (cough, fever, productive sputum, dyspnoea, chest pain or abnormal breath sounds); 2) radiographic pulmonary abnormalities that were at least segmental and were not explained by pre-existing or other known causes; and 3) positive detection of *M. pneumoniae* nucleic acid by PCR or mNGS from lower respiratory tract secretion (sputum and BALF), which were considered as microbiological evidence of infection.

All cases of pneumonia occurring more than 3 days after hospitalization were considered nosocomial and were excluded. Patients with HIV infection, neutropenia, or who were receiving immunosuppressive chemotherapy were excluded.

The diagnosis of ARDS was assigned to patients who met the Berlin definition criteria: 1) presence of acute hypoxemic respiratory failure; 2) onset within 7 days of insult, or new (within 7 days) or worsening respiratory symptoms; 3) bilateral opacities on chest x-ray or CT not fully explained by effusions, lobar or lung collapse, or nodules; and 4) cardiac failure not the primary cause of acute respiratory failure. We categorized patients into 3 mutually exclusive classes of ARDS severity using previous definitions based on degree of hypoxemia: 1) mild (200 mmHg ≤ PaO~2~/FIO~2~ \< 300 mmHg); 2) moderate (100 mmHg ≤ PaO~2~/FIO~2~ \< 200 mmHg); and 3) severe (PaO~2~/FIO~2~ \< 100 mmHg).

Microbiological tests {#Sec5}
---------------------

Patient specimens, including sputum, whole blood, and serum samples, were collected upon admission and during hospitalization for bacterial and viral testing. Microbiological tests were performed at the Department of Infectious Disease and Clinical Microbiology laboratories in our centers. Throat swabs, sputum, endotracheal aspiration or BALF were collected for *M. pneumoniae* PCR assay. All severe ARDS patients had *M. pneumoniae* infection confirmed by PCR assay or mNGS from lower respiratory tract secretion (sputum and BALF). PCR of pleural effusion fluid were also tested in some patients for the detection of *M. pneumoniae*.

Data collection {#Sec6}
---------------

Clinical information collected included the following: characteristics (age and sex), comorbidities, clinical symptoms (fever, cough, sputum, dyspnea, chest pain, rash, nausea, vomiting, abdominal pain, diarrhea and headache), clinical signs (body temperature, heart rate, respiratory frequency, blood pressure and crackles in the lungs), laboratory tests (whole-blood cell count and blood chemistry), and microbiological findings and images of the lung, including chest X-ray (CXR) and high resolution computed tomography (HRCT). Concomitant medications, respiratory support (HFNC, NIV, invasive mechanical ventilation, prone position and ECMO), complications, and outcomes were also recorded.

Statistical analysis {#Sec7}
--------------------

Pooled epidemiological, clinical, imaging, and laboratory data are shown as median with range for quantitative variables and as absolute and relative frequencies for qualitative variables. The enrolled patients were divided into two groups based on use of invasive mechanical ventilation. Continuous variables were compared using the Mann-Whitney U-test, whereas categorical data were compared using the Chi-squared test or the Fisher's Exact test, where appropriate. All comparisons were performed using the SPSS statistics package version 19.0. Differences were considered statistically significant when *p* was \< 0.05.

Results {#Sec8}
=======

Baseline characteristics of the included patients {#Sec9}
-------------------------------------------------

Between November 2017 and October 2019, 11 patients met criteria of severe *M. pneumoniae* pneumonia. Of the 11 patients, one patient was excluded due to diagnosis of lymphoma combined with adenovirus pneumonia. Therefore, 10 immunocompetent patients were included in the final analysis.

The age range of our patients was 15 to 53 (median 31) years. There were 6 male and 4 female patients. All cases were admitted in different months of the year except for January, February and September. Only one patient (case 9) had diabetes mellitus. The other 9 patients had no underlying diseases (Table [1](#Tab1){ref-type="table"}). Table 1Clinical characteristics and diagnostics for the patients with severe *M. pneumoniae* pneumoniaCase No.MaleAgeMonth of admissionTmax (°C)CoughDyspneaDiarrheaLength of onset to dyspnea (days)Length of onset to ICU admission (days)Ig GIgMPCR of sputumPCR of BALFPCR of pleural effusionNGS from BALFCombined Bacteria or virusLength of ICU stay (days)Length of hospital stay (days)Case 1Female34June40.6Dry coughYesYes1315----PositivePositiveNAPositiveAdenovirus1414Case 2Female26May40.6Dry coughYesYes1214++PositiveNANAPositiveRhinovirusStreptococcus720Case 3Female15Dec.40.5Productive coughYesYes1515++PositiveNANANANone615Case 4Male42May42Dry coughYesNo69----PositiveNANANARhinovirusEpstein-Barr virus1212Case 5Male32Apr.39.6Dry coughYesNo1214+--PositiveNANANARhinovirus1313Case 6Male44Mar.40Dry coughYesNo614+--PositiveNANANARhinovirus313Case 7Male53Nov.39.5Productive coughYesNo910+--PositiveNANANANone417Case 8Female17Aug.41.2Dry coughYesNo512++PositivePositivePositivePositiveAcinetobacter baumannii3333Case 9Male34Oct..39.6Dry coughYesNo911++PositivePositiveNAPositiveNone414Case 10Male17Nov39.8Dry coughYesYes33--+NANANAPositiveAcinetobacter baumannii918Mean(±SD)6/10(60%)31(13)40.4(0.8)10/10(100%)4/10(40%)9(4)11(4)+(70%)+(50%)931511(9)17(6.2)*Tmax* Maximum temperature, *NGS* Next-generation sequencing detection, *BALF* Bronchoalveolar lavage fluid, *NA* Not available, *PCR* Polymerase chain reaction

Microbiological findings {#Sec10}
------------------------

Seven (70%) and 5 (50%) patients had positive serum *M. pneumoniae* IgG and IgM, respectively. *M. pneumoniae* PCR of the sputum was performed in 9 (90%) cases, and was positive in all 9 cases. Three of the 9 cases had *M. pneumoniae* PCR from BALF at the same time, and all 3 cases (100%) were positive. Another patient was diagnosed with *M. pneumoniae* pneumonia through PCR of pleural effusion fluid. Five cases had mNGS from BALF, and all these 5 cases were positive for *M. pneumoniae* (Table [1](#Tab1){ref-type="table"}).

*Acinetobacter baumannii* was detected in 2 patients (20%) who were transferred from another hospital after ICU admission, but these were isolated from the lower respiratory tract (LRT) samples collected after more than 3 days of their ICU stay, and therefore were not considered as causative agents of ARDS together with *M. pneumoniae* (Table [1](#Tab1){ref-type="table"}).

Clinical features of symptoms and signs, laboratory tests and radiologic findings {#Sec11}
---------------------------------------------------------------------------------

### Symptoms and signs {#Sec12}

All 10 patients had cough and fever at the onset of illness. They presented with a high fever, with a median body temperature of 40.3 °C (range, 39.6 °C to 42.0 °C). Eight patients (80%) had dry cough and two patients had productive cough. Four patients (40%) had diarrhea and one patient (10%) had abdominal pain (Table [1](#Tab1){ref-type="table"}). Acute respiratory deterioration occurred 3 to 15 (median 9) days after the onset of symptoms. After the onset of dyspnea, patients usually progressed to acute respiratory failure. The mean time from symptom onset to ICU admission was 11 days (range, 3 to 15 days) (Table [1](#Tab1){ref-type="table"}). All 10 cases had tachypnea when admitted to the ICU, with mean respiratory rate of 27 breaths per minute (range, 21 to 33).

### Laboratory tests {#Sec13}

Arterial blood gas analysis at ICU admission of all patients revealed hypoxia, with a mean PaO~2~/FiO~2~ of 180 (range = 47 to 263) mmHg. White blood cell counts were low or in the normal range on the first day of admission. All patients had elevated serum aspartate aminotransferase (AST), lactate dehydrogenase (LDH) and hydroxybutyrate dehydrogenase (HBDH). Eight patients (80%) had elevated AST (44 U/L to 134 U/L). Four patients (40%) had elevated CK (457 U/L to 1052 U/L). Nine patients (90%) had elevated LDH and HBDH (328 U/L to 920 U/L, and 196 U/L to 637 U/L) (Attached file 1, E-Table [1](#MOESM1){ref-type="media"}). Nine patients were tested for cell-mediated immunity, immunoglobulins (serum IgG, IgA and IgM), and components (Attached file 2, E-Table [2](#MOESM2){ref-type="media"}).

### Characteristics of pleural effusions {#Sec14}

In our study, eight patients had unilateral pleural effusions, and only one patient had bilateral pleural effusions. Pleural effusion fluid was examined in 4 patients. The pleural effusion fluid was light yellow and clear in 2 patients, and were yellow but turbid in the other 2 patients. Routine pleural effusion tests demonstrated mononuclear cell dominant leukocyte populations (Attached file 3, E-Table [3](#MOESM3){ref-type="media"}).

### Radiologic findings {#Sec15}

All 10 patients had CXRs. CXRs revealed bilateral multi-lobular or segmental consolidation in nine (90%) patients. One patient's CXR showed diffuse peribronchial infiltration. All 10 patients underwent chest HRCT. Unilateral or bilateral consolidation and infiltration were found on HRCT scans of 9 patients (90%). Large areas of consolidation within a single lobe or several lobes (90%), followed by pleural effusion (80%), were the most common findings on HRCT (Fig. [1](#Fig1){ref-type="fig"}). Only the HRCT of case 9 showed peribronchial infiltration without consolidation and pleural effusion. Fig. 1Chest computed tomography (CT) on day 1, day 8--11, followed up after 1 months to 8 months of three patients (case1, case 4 and case 6). Three representative slices of the upper, middle and lower lobe were chosen

Respiratory mechanics and respiratory support {#Sec16}
---------------------------------------------

The average PaO~2~/FiO~2~ of all patients was 180 mmHg. Four (40%) cases had moderate ARDS (100 mmHg ≤ PaO~2~/FiO~2~ \< 200 mmHg), and three cases (30%) had severe ARDS (PaO~2~/FiO~2~ \< 100 mmHg). HFNC was applied in all patients (100%), with a median gas flow of 50 L/min (45-53 L/min) and FiO~2~ 0.48(0.35--0.5), but only two patients were sufficiently supported with HFNC. NIV was used in four patients with a median duration of 24(13--32) h, and one patient had NIV failure and needed intubation (Table [2](#Tab2){ref-type="table"}). Table 2The setting of respiratory support and the characteristics of respiratory mechanicsCase NoBreathing rate (breaths/min)PaO~2~/FiO~2~HFNC (hours)Setting of HFNCNIV (hours)Setting of NIVIMV (days)The mode and the initial parameter setting of IMVSPO~2~ before RMSPO~2~ after RMProne positionECMO (days)Resistance (L/cm H~2~O/S)Compliance (ml/cm H~2~O)Case 12719863Oxygen flow 40 L/MinFiO~2~ 0.6011CPAP 5cmH~2~O FiO~2~ 0.710P-A/C, Pi 12 cmH~2~OPEEPmax 16 cmH~2~O, FiO~2~ 1.073%97%Yes02034Case 22516285Oxygen flow 50 L/MinFiO~2~ 0.5033S/T 10/5cmH~2~OFiO~2~ 0.45--NANANANO0NANACase 32111820Oxygen flow 60 L/MinFiO~2~ 0.50--NA3P-A/C, Pi 12 cmH~2~OPEEPmax 16 cmH~2~O, FiO~2~ 1.090%98%Yes01441Case 433155158Oxygen flow 50 L/MinFiO~2~ 0.45--NA--NANANAYes0NANACase 5245643Oxygen flow 60 L/MinFiO~2~ 0.45--NA8P-A/C, Pi 10 cmH~2~OPEEPmax 14 cmH~2~O, FiO~2~ 1.092%99%Yes01554Case 62923035Oxygen flow 45 L/MinFiO~2~ 0.35--NA--NANANANA0NANACase 72426339Oxygen flow 45 L/MinFiO~2~ 0.3520CPAP 6cmH~2~OFiO~2~ 0.28--NANANANA0NAN ACase 8304717Oxygen flow 45 L/MinFiO~2~ 0.26--NA15P-A/C, Pi 10 cmH~2~OPEEPmax10 cmH~2~O, FiO~2~ 1.094%94%Yes61422Case 92726054Oxygen flow 50 L/MinFiO~2~ 0.528S/T 10/6cmH~2~OFiO~2~ 0.5--NANANANA0NANACase 10309630Oxygen flow 50 L/MinFiO~2~ 0.5--NA7P-A/C, Pi 10 cmH~2~OPEEPmax12 cmH~2~O, FiO~2~ 1.0NANANo5NANATotal/median (IQR)27(21--33)180(47--263)41(28--69)50 (45--53)L/min0.48 (0.35--0.5)24(13--32)8(5--13)PEEPmax 14 cm H~2~O(11--16)91%(77--94%)98%(95--99%)YES4 (40%)5.5(5--6)15(14--19)38(25--51)*NIV* Non-invasive ventilation, *HFNC* High-flow nasal cannula, *IMV* Invasive mechanical ventilation, *ECMO* Extracorporeal membrane oxygenation support

Invasive mechanical ventilation (IMV) was carried out in 5 patients (50%). High airway resistance (median 15 L/cmH~2~O/s) and low respiratory system compliance (median 38 ml/cmH~2~O) was observed in all 5 cases. Recruitment maneuver (RM) was applied in 4 cases, with 1 patient not responsive to RM, and 4 cases were put into prone position. The maximum PEEP was 14 cmH~2~O (range, 11--16 cmH~2~O). Two cases (20%) needed ECMO support with median support duration of 5.5 days (Table [2](#Tab2){ref-type="table"}). As shown in Table [2](#Tab2){ref-type="table"}, Case 8 had the worst compliance and was unresponsive to RM, and ECMO was established. Case 1, case 3, and case 5 were responsive to RM and prone position.

Treatment {#Sec17}
---------

All 10 patients did not receive fluoroquinolones at the onset of their illness, and switched to fluoroquinolones 8.7 ± 3.5 days after onset. All patients received β-lactams treatment as first therapy, and 5 patients received treatment combined with macrolides before their admission to ICU. After ICU admission, moxifloxacin were given to all 10 patients.

No patients in our case series received corticosteroid therapy.

Outcomes {#Sec18}
--------

All patients survived in the ICU and were discharged from the hospital. The mortality of our cases was 0%. The average length of ICU stay was 11 days, and the average length of hospital stay was 17 days.

Comparison of intubated and non-intubated cases in MPP patients {#Sec19}
---------------------------------------------------------------

As shown in Table [3](#Tab3){ref-type="table"}, compared to non-intubated patients, patients in intubated group were younger, were less likely to be male, had lower PaO~2~/FiO~2~ and higher APACHE II scores, and had higher procalcitonin and neutrophil proportion at ICU admission. Table 3Comparisons between patients with IMV and non-IMV (Median, IQR)Non-intubated group\
*n* = 5IMV group\
*n* = 5*P* valueMale(n,%)4 (80%)2 (40%)0.003\*Age (year)42 (30--49)17 (16--33)0.032\*APACHEII6 (4--12)17 (11--21)0.028\*PaO~2~/FiO~2~230 (159--262)96 (51--158)0.032\*Lactate0.9 (0.7--1.3)1.3 (1.2--1.7)0.056Breathing rate (breaths/min)26 (25--31)27 (23--29)0.690Tmax((°C))40 (39.5--41.3)40 (39.7--40.9)0.841Procalcitonin0.175 (0.14--0.195)1.05 (0.45--2.09)0.016\*White blood cell count(10^9^/L)4.5 (3.8--7.3)7.6 (5.5--8.7)0.151Neutrophil proportion(%)73 (54--82)92 (83--94)0.016\*AST (U/L)81 (33--102)100 (41--121)0.548Albumin (g/L)29 (28--34)32 (26--39)1.0Pre-albumin (g/L)0.08 (0.02--0.15)0.03 (0.03--0.04)0.571Creatine (umol/L)55 (47--69)43 (35--76)1.0C-reactive protein (CRP, mg/L)17 (6--48)93 (11--209)0.286Erythrocyte sedimentation rate (ESR,mm/h)25 (5.5--28.5)12 (4--25)0.675Length of onset to ICU admission (days)11 (9.5--14)14 (7.5--15)0.421Length of ICU stay (days)4 (3--18.5)13 (17.5--23.5)0.056*APACHE II* Acute physiological and chronic health evaluation II score; \**P* \< 0.05

Discussion {#Sec20}
==========

To our knowledge, our study is the first and largest case series to evaluate diagnostic and therapeutic modalities in severe *M. pneumoniae* pneumonia induced ARDS. Our main findings are as follows: 1) early and rapid diagnosis for severe *M. pneumoniae* pneumonia with ARDS was achieved with PCR/mNGS test of samples from the lower respiratory tract and pleural effusions; 2) CT findings mainly showed alveolar patterns with bilateral consolidations rather than interstitial patterns; 3) respiratory mechanics showed low respiratory system compliance and high airway resistance; 4) 50% of *M. pneumoniae* induced ARDS were adequately supported with HFNC or NIV, 50% required intubation, RM and prone position were effective in 30% intubated cases, and 20% needed ECMO support; 5) when early anti-mycoplasmal drugs together with sufficient respiratory support are given, the survival rate was high with no need for corticosteroids; and 6) younger patients with lower PaO~2~/FiO~2~ and APACHE II scores, and higher PCT and higher neutrophil cell proportion at ICU admission were more likely to require intubation.

In our study, the clinical manifestations of severe *M. pneumoniae* pneumonia induced ARDS were primarily dry cough, high fever, and acute respiratory failure with bilateral consolidations on radiologic examination. Respiratory failure occurred a median of 9 days (range, 3 to 15 days) after onset of symptoms, similar to the previous descriptions \[[@CR3], [@CR29]\]. However, these clinical features are not specific for early recognition and diagnosis of severe *M. pneumoniae* pneumonia. Therefore, early and precise laboratory detection of *M. pneumoniae* infection is essential to prevent deterioration. Previous methods, such as mycoplasma culture and serological tests, which may require several weeks, are not practical. As presented in our study, early definitive diagnosis is now dependent on PCR or mNGS \[[@CR25]\], which had high specificity and sensitivity. Thus, further development of these relatively new diagnostic tools is warranted, and should be applied in cases of severe CAP induced ARDS with suspected *M. pneumoniae* infection.

Furthermore, our study found that most of our cases had pleural effusion, and PCR was positive for *M. pneumoniae* in pleural effusion fluid. Similar findings were also reported in a previous case report \[[@CR24]\]. Therefore, in patients with dry cough and difficulty obtaining a lower respiratory sample, early PCR/mNGS for *M. pneumoniae* using pleural effusion fluid may be an option. As ARDS is a clinical syndrome with many different causes and may induced by some less common pathogens, mNGS is used in our ICU for early detection of possible unknown etiology, and we found that mNGS had a good value in diagnosis for *M. pneumoniae* in our cases. However, in most cases mNGS is more appropriate to be used for patients with unknown etiology, and may not be suitable for routine examination of some common pathogens such as ADV, RSV, and *M. pneumoniae*. Thus, once commercial PCR kits are available for diagnosis of *M. pneumoniae* infection, it is not necessary to detect *M. pneumoniae* using mNGS as a primary option.

In both our case series and previously reported cases of *M. pneumoniae* associated ARDS, deterioration of the clinical state presumably due to a significant period of inadequate antibiotic treatment \[[@CR29], [@CR30]\]. In a review of severe or fatal *M. pneumoniae* pneumonia, the average duration from onset of infection to the development of respiratory failure was 11.2 days (range, 5--21 days) \[[@CR29]\]. Chan and Miyashita et al. reported durations of 10--15 and 9.3 days, respectively, from onset to first administration of appropriate anti-mycoplasma agents \[[@CR4], [@CR5]\]. The duration of an average of 9 days to change the treatment from our study was similar to the previous studies. Therefore, our management would still be considered as late intervention, and the delay as a risk factor for development of respiratory failure and ARDS. Earlier recognition of *M. pneumonia*e in the differential diagnosis and earlier initiation of appropriate antibiotics would potentially prevent *M. pneumoniae* pneumonia from progressing to ARDS.

Furthermore, more awareness is needed on the emergence of macrolide-resistant *M. pneumoniae* infection in adults \[[@CR31], [@CR32]\]. A previous report from our center found the rate of resistance to macrolides was 88.3% of the isolated *M. pneumoniae,* and all resistant strains harbored A2063G mutations. The isolated macrolide-resistant *M. pneumoniae* were resistant to erythromycin, and also showed cross-resistance to clarithromycin and azithromycin. All isolates were sensitive to tetracyclines and fluoroquinolones. Moxifloxacin was more active than ciprofloxacin and levofloxacin \[[@CR33]\]. However, sequencing of macrolide resistance genes is not a routine test in clinical practice in our centers, and we did not perform sequencing for macrolide resistance genes in our cases. We speculated that we have the similar high rate of resistance and similar type of resistant genes in our case series. Thus, early fluoroquinolones were considered as first line treatment for *M. pneumonia* induced severe ARDS cases in adults.

A previous epidemiological study from one of our centers (Beijing Chao-Yang Hospital) that routinely screened for *M. pneumoniae* in outpatients during 2011--2016 determined that only 14 patients out of 1127 patients (1.2%) with *M. pneumoniae* infection needed ICU admission \[[@CR21]\]. However, after that study concluded, *M. pneumoniae* infection was only routinely screened in patients with a diagnosis of community acquired pneumonia who were hospitalized in our general ward or admitted to our ICU. During our study period, 11 of 418 severe CAP were admitted to our ICU and were diagnosed with *M. pneumoniae* pneumonia (2.3%). Additionally, as shown in Table [1](#Tab1){ref-type="table"} in our study, the first LRT sample for *M. pneumoniae* was collected on an average of 11 ± 4 days after the onset of symptoms. The higher rate of *M. pneumoniae* pneumonia in our case series suggests that early detection for the pathogen may be needed to start an early intervention and proper treatment.

The 3 patients with mild ARDS in our study were successfully supported by HFNC and NIV without intubation. One patient with moderate ARDS was successfully supported with a combination of HFNC and awake prone positioning, which proved safe and effective in moderate ARDS patients by our team in a prospective study \[[@CR34]\]. HFNC or NIV, combined with early prone positioning, may be a new support strategy for acute respiratory failure in *M. pneumoniae* indunced mild to moderate ARDS patients.

Although the radiologic findings showed a diffuse alveolar pattern with consolidations and the respiratory mechanics showed decreased respiratory system compliance, most intubated patients were responsive to RM and prone positioning during invasive ventilation, with a maximum PEEP of 11--16 (median 14) cmH~2~O was applied. However, two cases deteriorated to severe hypoxia despite anti-mycoplasmal therapy and invasive ventilation, eventually requiring ECMO support. In a recent case report and literature review for use of ECMO in *M. pneumoniae* associated ARDS, the mean ECMO run was 232 h/9.68 days \[[@CR28]\], similar to that of our cases. The overall survival rate for 22 cases of *M. pneumoniae* requiring ECMO with reported outcome was 72.7%(16/22), demonstrating that ECMO may be safely and effectively used to treat severe ARDS caused by *M. pneumoniae* infection \[[@CR28]\].

Previous reports support the hypothesis that the severity of the disease and pulmonary infiltrates may be directly correlated with the level of the individual immune response. However, in our study, we did not observe significant increases of cell or humoral immunity as demonstrated by T cell subset cell count or immunoglobulin levels in more severe disease. Most interestingly, we found that with appropriate respiratory support and anti-mycoplasmal therapy, all patients had a rapid clinical improvement. Therefore, no corticosteroids were given, and all patients finally recovered from ARDS without corticosteroid use. Prolonged or inappropriate use of corticosteroids may cause excess downregulation of cell-medicated immunity and result in immunosuppression, making individuals more susceptible to more severe *M. pneumoniae* infection or opportunistic infections. A recent case report revealed that *M. pneumoniae* associated ARDS had no elevated pulmonary vascular permeability, and was successfully treated using low-dose short-term hydrocortisone, suggesting that pulmonary infiltration in ARDS caused by *M. pneumoniae* does not match the criteria of permeability edema observed in typical ARDS \[[@CR35]\]. Therefore, careful consideration is required when deciding whether to use high dose corticosteroid in the future cases similar to ours.

There are several limitations for our study. First, performing statistical analysis on a small sample size was prone to bias, potentially yielding spurious findings. Increasing the sample size and collecting more cases in a further study may avoid this kind of limitation. Second, this study is a retrospective study with the associated limitations on complete data collection.

Conclusions {#Sec21}
===========

In conclusion, early and rapid diagnosis for severe *M. pneumoniae* pneumonia with ARDS can be achieved by PCR/mNGS test in samples from lower respiratory tract or pleural effusion. In our case series, half of *M. pneumoniae* induced ARDS cases were adequately supported with HFNC or NIV and 50% required intubation. RM and prone position were effective in 30% of intubated cases, and 20% needed ECMO support. When early anti-mycoplasmal therapy was given together with sufficient respiratory support, the survival rate was high with no need for corticosteroid use.
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**Additional file 1.**E-Table 1. The laboratory findings for the patients with severe *M. Pneumoniae* pneumonia on the first day of admission. **Additional file 2.** E-Table 2. The result of pleural effusion biochemistry and pleural effusion routine of the 4 severe *M. pneumoniae* pneumonia. **Additional file 3.** E-Table 3. Cell-mediated immunity and Humoral immunity on the immunocompetent patients with severe *M. Pneumoniae* pneumonia on the first day of admission.
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